New hope for rare blood cancer: which drug combo works best?
NCT ID NCT02844322
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two different drug combinations in 35 people newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. The goal was to see which combination better controls the disease and improves survival without progression. Participants received either rituximab or bortezomib along with cyclophosphamide and dexamethasone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTRÖM MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shuhua Yi
Tianjin, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug duo shows promise for rare blood cancer
- New PET tracer aims to spot hidden cancers without biopsy
- New hope for rare blood cancer: targeted drug shows promise in early trial
- New Two-Step transplant shows promise for blood cancer patients
- New drug targets Hard-to-Treat blood cancers in chinese trial
- New drug combo shows promise for blood cancer patients